Table 2 ΔΔQTcF across study treatments and post-dose time points
Time post-dose (h) | Lucerastat | Moxifloxacin | |
|---|---|---|---|
1000Â mg | 4000Â mg | 400Â mg | |
n = 36 | n = 36 | n = 35 | |
0.5 | − 2.3 (− 4.0, − 0.7) | − 1.1 (− 2.8, 0.5) | 3.5 (1.9, 5.2) |
1.0 | 0.7 (− 1.0, 2.4) | 0.5 (− 1.2, 2.3) | 10.7 (9.0, 12.5) |
1.5 | 1.1 (− 1.0, 3.1) | 2.2 (0.2, 4.3) | 13.9 (11.8, 16.0) |
2.0 | 0.5 (− 1.5, 2.5) | 0.9 (− 1.0, 2.9) | 12.8 (10.8, 14.8) |
2.5 | 1.3 (− 0.7, 3.4) | 2.6 (0.6, 4.7) | 13.5 (11.5, 15.6) |
3.0 | 0.4 (− 1.7, 2.4) | 1.1 (− 0.9, 3.1) | 13.4 (11.3, 15.4) |
3.5 | − 0.8 (− 2.9, 1.3) | 0.4 (− 1.7, 2.5) | 13.0 (10.9, 15.1) |
4.0 | 0.2 (− 2.1, 2.4) | 1.0 (− 1.3, 3.2) | 12.8 (10.5, 15.1) |
6.0 | 0.0 (− 3.0, 3.0) | − 0.3 (− 3.3, 2.7) | 9.4 (6.4, 12.5) |
8.0 | 0.7 (− 1.8, 3.3) | 1.1 (− 1.5, 3.7) | 9.9 (7.3, 12.5) |
12.0 | 1.2 (− 1.4, 3.8) | 0.6 (− 2.1, 3.2) | 8.9 (6.2, 11.5) |
24.0 | − 0.6 (− 2.8, 1.5) | − 1.7 (− 3.8, 0.4) | 3.9 (1.8, 6.0) |
36.0 | 0.7 (− 2.4, 3.7) | − 1.5 (− 4.6, 1.5) | 2.1 (− 0.9, 5.2) |